Brachytherapy for pediatric tumors
โ Scribed by Subir Nag; Douglas B Tippin
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 176 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1538-4721
No coin nor oath required. For personal study only.
โฆ Synopsis
Purpose: Pediatric tumors are generally managed with a multi-modality treatment program that includes surgery, chemotherapy, and teletherapy. The use of teletherapy in young children can result in significant long-term toxicity (especially retardation of growth of bones and organs). The use of brachytherapy is an attractive alternative because brachytherapy irradiates small volumes and can thus potentially minimize complications.
Methods and Materials:
The brachytherapy techniques used are similar to those used in adults. Low-dose-rate brachytherapy with manually-afterloaded removable 192 Ir is commonly used though it is associated with some radiation exposure hazards. Low energy radionuclides and remote afterloading technology have been used to reduce the radiation exposure hazards. Teletherapy is often added in the treatment of more extensive tumors, especially in older children. Results: Brachytherapy (as the sole radiation modality) to small volumes in conjunction with chemotherapy and surgery has produced good local control with growth preservation and acceptable late complications in selected patients with localized tumors. Conclusion: Brachytherapy increases local control with a decrease in the probability of late complications (especially altered bone and organ growth) in comparison to EBRT. Low energy radionuclides and remote afterloading technology (HDR, IOHDR, and PDR) have been used to extend treatment to infants and younger children while reducing the radiation exposure to patients, family, and medical personnel.
๐ SIMILAR VOLUMES
Purpose: To evaluate the efficacy and toxicity of intraoperative high-dose-rate brachytherapy (IOHDR) in the management of pediatric solid tumors. ## Methods and Materials: The records of 66 pediatric patients who underwent IOHDR for a solid tumor from February 1993 through December 2002 were ret
{ Sylvain Baruchel is the Principal Investigator of an industry sponsored study (Schering-Plough). He receives no monetary compensation. Grant sponsor: Temodal 1 (the manufacturers of temozolomide), Schering Plough, Inc. (for the Phase I Clinical Trial).
Promising results have been obtained using brachytherapy in the treatment of brain tumors. Very low-dose rate brachytherapy (60-100 Gy given at 0.05-0.10 Gy/h) has been used for low-grade gliomas, resulting in 5- and 10-year survival probabilities of 85% and 83% for pilocytic astrocytomas and 61% an
For nearly 20 years, interstitial brachytherapy has been used as adjuvant treatment for malignant brain tumors in both prospective clinical trials and as part of standard therapy. Numerous publications analyzing the results of this treatment seem to indicate an improvement in median survival for hig